Dermatitis News and Research

Latest Dermatitis News and Research

YM BioSciences' nimotuzumab Phase II trials: FDA advises patient enrollment

YM BioSciences Inc., announced that the FDA has advised the Company that it may now enroll patients at US clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer (NSCLC) patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC. Current NSCLC palliative treatment and treatment for brain metastases is radiation alone.

27 Jan 2010

NTNU: 40% of two-year-olds report allergy-related disorders

Allergies and asthma are a continuing health problem in most developed countries, but just how do these ailments develop over the course of a childhood? In a population-based study designed to help answer this question, researchers at the Norwegian University of Science and Technology (NTNU) found that 40 per cent - or two of five -- of nearly 5,000 two-year-olds had at least one reported allergy-related disorder. The most common symptom was wheezing, which was reported in 26 per cent of all children in the study, says Ingeborg Smidesang, a PhD candidate in the university's Faculty of Medicine, and the primary author of the study.

25 Jan 2010

Dermatological nuisance caused by toilet seats making a comeback in pediatricians' offices

Considered a dermatological nuisance that was long gone, skin irritations caused by toilet seats appear to be making a comeback in pediatricians' offices, according to research led by Johns Hopkins Children's Center investigator Bernard Cohen, M.D.

25 Jan 2010

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Amgen today announced that detailed results from two pivotal Phase 3 studies evaluating Vectibix® (panitumumab) in combination with chemotherapy for the first and second-line treatment of metastatic colorectal cancer (mCRC) (the PRIME '203' and '181' trials, respectively) will be presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in Orlando, Florida from Jan. 22-24, 2010.

21 Jan 2010

PhotoMedex regains compliance with Nasdaq minimum bid price requirement

PhotoMedex, Inc. today announced that it has regained compliance with the minimum bid price requirement of The Nasdaq Stock Market under Nasdaq Listing Rule 5450(a)(1).

21 Jan 2010

Study identifies new mechanism that causes allergic response in people

WHAT: A new study in human cells has singled out a molecule that specifically directs immune cells to develop the capability to produce an allergic response. The signaling molecule, called thymic stromal lymphopoietin (TSLP), is key to the development of allergic diseases such as asthma, atopic dermatitis (eczema) and food allergy.

21 Jan 2010

YM BioSciences announces results of cancer antibody-radionuclide conjugate development collaboration

YM BioSciences Inc. today announced results of a collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The approach has successfully concluded its first series of proof-of-principle experiments establishing promise for future development and application.

12 Jan 2010

PhotoMedex, Galderma Laboratories enter into co-promotion agreement for photodynamic therapy application

PhotoMedex and Galderma Laboratories, L.P. have entered into a co-promotion agreement for Galderma’s photodynamic therapy application for the treatment of actinic keratoses (“AK”).

11 Jan 2010

Hi-Tech Pharmacal receives clearance from FDA to market Tropazone lotion

Hi-Tech Pharmacal Co., Inc. announced today that it received clearance from the FDA to market Tropazone™ lotion, a prescription dermatological product which will be promoted by Hi-Tech’s branded marketing subsidiary, ECR Pharmaceuticals Co., Inc. The product is indicated for the treatment of various dermatological conditions including atopic dermatitis, allergic contact dermatitis, and radiation dermatitis.

8 Jan 2010

ZymoGenetics announces pricing of public offering of 14,000,000 shares

ZymoGenetics, Inc. today announced that it has priced an underwritten public offering of 14,000,000 shares of its common stock at a price of $6.00 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, will be approximately $79,000,000.

8 Jan 2010

Ceragenix Pharmaceuticals and BioPro Pharmaceutical enter into agreement to commercialize EpiCeram

Ceragenix Pharmaceuticals, Inc. (“Ceragenix”), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the “Agreement”) with BioPro Pharmaceutical, Inc. (“BioPro”), to commercialize EpiCeram®, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan (the “Territories”).

7 Jan 2010

Positive results from Onset Therapeutics' BenzEFoam Emollient Foam skin moisturization study

Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, today announced positive results from a skin moisturization study that compared the Company’s recently launched BenzEFoam™ (benzoyl peroxide 5.3%) Emollient Foam to a market leading combination gel containing clindamycin 1% - benzoyl peroxide 5%. BenzEFoam™ Emollient Foam is indicated for the topical treatment of mild to moderate acne vulgaris and is the first prescription foam formulation containing benzoyl peroxide as the active ingredient.

16 Dec 2009

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.

14 Dec 2009

Enrollment of patients for Phase IIb clinical trial of WBI-1001 commenced

Welichem today announced that the Company has begun to enroll patients in a Phase IIb clinical trial with its lead candidate, WBI-1001. The Phase IIb clinical trial is a double-blinded, placebo-controlled, 12-week-treatment study.

12 Dec 2009

Update on proposed transaction that will lead to the merger of Cytopia into YM BioSciences provided

YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today provided an update on the proposed transaction which would result in the merger of Cytopia Ltd. into YM, details of which were announced on October 5, 2009.

11 Dec 2009

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

In a large Phase III clinical trial, Tasigna (nilotinib capsules) demonstrated greater efficacy over Gleevec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana.

11 Dec 2009

YM BioSciences announces results of collaborative antibody development program

YM BioSciences Inc., today announced the first results of a collaborative program between YM and the National Research Council of Canada's Biotechnology Research Institute (NRC-BRI). Utilizing YM's IntelliMab(TM) technology, the program is designed to generate novel antibodies that target cell surface receptors associated with cancer, uniquely optimized to produce efficacy with reduced toxicities.

10 Dec 2009

Positive results from DermaGen's Phase I/IIa AMP study of atopic dermatitis

DermaGen AB - part of the Karolinska Development dermatology and wound healing company "Pergamum" - announced that Dermagen AB has received promising results from a clinical Phase I/IIa study. DermaGen AB is developing a novel antimicrobial peptide (AMP) treatment for atopic dermatitis. Atopic dermatitis is a chronic inflammatory skin disease where dry skin and the skin's weakened barrier function make patients susceptible to colonization by microorganisms, a triggering or exacerbating factor of the disease.

2 Dec 2009

Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced preliminary data for the company’s PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis.

1 Dec 2009

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Bavarian Nordic A/S announced today that the company expects to file a New Drug Submission (NDS) for its third-generation smallpox vaccine, IMVAMUNE(R) with the Canadian Authorities, Health Canada in 2010. If successful, this would be the first marketing approval of IMVAMUNE(R).

30 Nov 2009

Dermatitis News and Research

Latest Dermatitis News and Research

YM BioSciences' nimotuzumab Phase II trials: FDA advises patient enrollment

NTNU: 40% of two-year-olds report allergy-related disorders

Dermatological nuisance caused by toilet seats making a comeback in pediatricians' offices

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

PhotoMedex regains compliance with Nasdaq minimum bid price requirement

Study identifies new mechanism that causes allergic response in people

YM BioSciences announces results of cancer antibody-radionuclide conjugate development collaboration

PhotoMedex, Galderma Laboratories enter into co-promotion agreement for photodynamic therapy application

Hi-Tech Pharmacal receives clearance from FDA to market Tropazone lotion

ZymoGenetics announces pricing of public offering of 14,000,000 shares

Ceragenix Pharmaceuticals and BioPro Pharmaceutical enter into agreement to commercialize EpiCeram

Positive results from Onset Therapeutics' BenzEFoam Emollient Foam skin moisturization study

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Enrollment of patients for Phase IIb clinical trial of WBI-1001 commenced

Update on proposed transaction that will lead to the merger of Cytopia into YM BioSciences provided

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

YM BioSciences announces results of collaborative antibody development program

Positive results from DermaGen's Phase I/IIa AMP study of atopic dermatitis

Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Dermatitis News and Research

Latest Dermatitis News and Research

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in